



NDA 16-678 / S-105
NDA 16-697 / S-096
NDA 16-689 / S-105
NDA 16-696 / S-097
NDA 16-683 / S-100
NDA 16-687 / S-102

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Linda Coleman
Director, Regulatory Affairs
32650 N. Wilson Rd.
Round Lake, IL 60073

Dear Ms. Coleman:

Please refer to your Supplemental New Drug Applications (sNDAs) dated December 19, 2012, received December 20, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA/Supplement	Drug
NDA 16-678 / S-105	5% Dextrose and 0.9% Sodium Chloride Injection, USP in Plastic Container
NDA 16-697 / S-096	2.5% Dextrose and 0.45% Sodium Chloride Injection, USP in Plastic Container
NDA 16-689 / S-105	5% Dextrose and 0.2% Sodium Chloride Injection, USP in Plastic Container
NDA 16-696 / S-097	10% Dextrose and 0.9% Sodium Chloride Injection, USP in Plastic Container
NDA 16-683 / S-100	5% Dextrose and 0.45% Sodium Chloride Injection, USP in Plastic Container
NDA 16-687 / S-102	5% Dextrose and 0.33% Sodium Chloride Injection, USP in Plastic Container

These “Changes Being Effected” supplemental new drug applications provide for the following changes to the package inserts:

- Precautions section: add the risk of air embolism (Viaflex labels only), rearranged and updated language in subsections
- Precautions and Pediatric Use sections: add glucose monitoring and the risk of hypoglycemia and hyperglycemia
- Precautions Pediatric Use and Adverse Reactions sections: add the risk of hyponatremia
- Adverse Reactions section: add anaphylactic reactions

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

NDA 16-678 / S-105
NDA 16-697 / S-096
NDA 16-689 / S-105
NDA 16-696 / S-097
NDA 16-683 / S-100
NDA 16-687 / S-102
Page 3

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
09/10/2013